<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566487</url>
  </required_header>
  <id_info>
    <org_study_id>353-09</org_study_id>
    <nct_id>NCT01566487</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition</brief_title>
  <official_title>Randomized, Open-Label, Balanced, Two-treatment, Two-period, Two-sequence, Crossover, Multicentric Experimental Bioequivalence Study of Quetiapine Fumarate Film-coated Tablets 300 mg (Test)and Seroquel Film-coated Tablets 300 mg (Reference) Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomised, balanced, two-treatment, two-period, two-sequence,&#xD;
      crossover, multicentric experimental bioequivalence study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study was to compare the bioavailability and characterise the&#xD;
      pharmacokinetics profile of the sponsor formulation Quetiapine fumarate tablets 300 mg of Dr.&#xD;
      Reddy's Laboratories Limited, India with respect to reference formulation Seroquel tablets&#xD;
      300 mg of Astrazeneca Pharmaceuticals, USA in adults schizophrenia patients under fasting&#xD;
      condition.&#xD;
&#xD;
      54 subjects were dosed and were enrolled in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>Period 1 - Pre-dose in day 3, 4 and 5 and period 2 pre dose in day8,9 and 10 and 0.25,0.5,0.75,1.25,1.5,1.75,2,2.5,3,4,6,8,10 &amp; 12 hrs post-dose on day 5 and day 10</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Quetiapine fumarate tablets 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seroquel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine fumarate</intervention_name>
    <description>Quetiapine fumarate tablets 300mg</description>
    <arm_group_label>Quetiapine fumarate tablets 300 mg</arm_group_label>
    <arm_group_label>Seroquel</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent for participation in the study by the patient and Patient's&#xD;
             Legally Acceptable Representative (LAR). If the patient or his/her legally acceptable&#xD;
             representative is unable to read/write - an impartial witness should be present during&#xD;
             the entire informed consent process who must append his/her signatures to the consent&#xD;
             form.&#xD;
&#xD;
          -  Schizophrenic patients, between 18 and 55 years of age (inclusive).&#xD;
&#xD;
          -  Patient has a documented clinical diagnosis of stable schizophrenia (DSM IV-TR)&#xD;
             controlled by a stable 300 mg Quetiapine regimen given at 12-hour intervals from at&#xD;
             least 2 weeks prior to the first dosing, as confirmed by Principal Investigator&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18 and 35 (inclusive). calculated as weight in&#xD;
             kg/height in m2.&#xD;
&#xD;
          -  Not having any significant diseases or clinically significant abnormal findings except&#xD;
             schizophrenia during screening, medical history, physical examination, laboratory&#xD;
             evaluations, 12-lead ECG recordings and Chest X ray (Postero-anterior view).&#xD;
&#xD;
          -  The investigator must ensure that the respective hepatic, renal, haematopoietic,&#xD;
             cardiac and respiratory functions are appropriate to include the patient in the study.&#xD;
&#xD;
          -  Able to comply with study procedures in the opinion of the investigator.&#xD;
&#xD;
          -  In case of female patient the serum pregnancy test at screening visit must be&#xD;
             negative.&#xD;
&#xD;
          -  Sexually active women, unless surgically sterile (at least 6 months prior to Study&#xD;
             drug administration) or postmenopausal for at least 12 consecutive months, must use an&#xD;
             effective method of avoiding pregnancy (including oral, transdermal, or implanted&#xD;
             contraceptives [any hormonal method in conjunction with a secondary method],&#xD;
             intrauterine device, female condom with spermicide. diaphragm with spermicide.Absolute&#xD;
             sexual abstinence, use of condom with spermicide by sexual partner or sterile [at&#xD;
             least 6 months prior to Study drug administration] sexual partner) for at least 4&#xD;
             weeks prior to study drug administration,during study and up to 30 days after the last&#xD;
             dose of study drug. Cessation of birth control after this point should be discussed&#xD;
             with a responsible physician. (It is investigator's responsibility to ensure that&#xD;
             above points regarding an effective method of avoiding pregnancy are discussed with&#xD;
             patient/LAR in detail and patient agreed for this and it is documented in source&#xD;
             document. The investigator should ensure that the patient is using an effective method&#xD;
             of avoiding pregnancy as per protocol).&#xD;
&#xD;
          -  In case of Male patients: Either partner or patient must use an effective method of&#xD;
             avoiding pregnancy for at least 4 weeks prior to study drug administration, during&#xD;
             study and up to 30 days after the last dose of study drug. Cessation of birth control&#xD;
             after this point should be discussed with a responsible physician.&#xD;
&#xD;
          -  (It is investigator's responsibility to ensure that above points regarding an&#xD;
             effective method of avoiding pregnancy are discussed with patient/LAR in detail and&#xD;
             patient agreed for this and it is documented in source document. The investigator&#xD;
             should ensure that the patient is using an effective method of avoiding pregnancy as&#xD;
             per protocol).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity/allergy or idiosyncratic reaction to Quetiapine or its&#xD;
             excipients.&#xD;
&#xD;
          -  Clinically significant illnesses (including hypotensive episodes and systemic&#xD;
             infection) or surgery within 4 weeks prior to the first dosing.&#xD;
&#xD;
          -  Current or relevant history of serious. severe or unstable psychiatric illness&#xD;
             (Meeting the criteria for any other (Diagnostic and Statistical Manual of Mental&#xD;
             Disorders, 4th Edition (DSM-IV) AXIS I) except schizophrenia.&#xD;
&#xD;
          -  History of syncope or orthostatic hypotension&#xD;
&#xD;
          -  Ingestion of any medication other than listed below at any time in 10 days before the&#xD;
             first study drug administration. In any such case Patient selection will be at the&#xD;
             discretion of the Principal Investigator.&#xD;
&#xD;
        Following is the list of permissible medications, provided, the patients are on a stable&#xD;
        regimen at least I0 days prior to and throughout the study.&#xD;
&#xD;
        Alprazolam, Fluoxetin, Imipramine, Haloperidol, Risperidone. (Refer Appendix 4 for list of&#xD;
        nonpermissible medication)&#xD;
&#xD;
          -  A history of alcohol or drug dependence by DSM-IV criteria within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Smokers who smoke 10 or more than 10 cigarette/day or inability to abstain from&#xD;
             smoking during the study&#xD;
&#xD;
          -  Donation of blood (≥ 1 unit or 350 mL) within 90 days prior to receiving the first&#xD;
             dose of study medication or during the study.&#xD;
&#xD;
        Note: In case the blood loss is less than or equol to 200 mL; patient may be dosed 60 days&#xD;
        after blood donation.&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen or HCV antibodies.&#xD;
&#xD;
          -  Positive test for HIV infection.&#xD;
&#xD;
          -  ECG abnormalities (clinically relevant), vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mnHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg or patient on any antihypertensive medication or heart rate less than 50&#xD;
             or over 100 bpm) or significant orthostatic hypotension (i.e.. a drop in systolic&#xD;
             blood pressure of 30 mmHg or more and/or a drop in diastolic blood pressure of 20 mmHg&#xD;
             or more on standing) at screening. Patients with vital signs values no more than 5%&#xD;
             out of the specified range but considered stable could be included in the study at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
          -  Any condition1 Abnormal baseline findings that in the investigator's judgement might&#xD;
             increase the risk to the patient or decrease the chance of obtaining satisfactory data&#xD;
             needed to obtain the objective of the study.&#xD;
&#xD;
          -  The receipt of an investigational product or participation in a drug research study&#xD;
             within a period of 30 days prior to the first dose of study medication.&#xD;
&#xD;
        Note: Elimination half-life of the study drug should be taken into consideration for&#xD;
        inclusion of the Patient in the study.&#xD;
&#xD;
          -  Psychosis judged to be the direct physiological effect of an abused medication or&#xD;
             substance.&#xD;
&#xD;
          -  Positive testing for the drugs of abuse (amphetamines, barbiturates ,benzodiazepines,&#xD;
             cocaine, morphine, marijuana) done by urine scan at Screening. (Except for alprazolam&#xD;
             which is a permissible medication).&#xD;
&#xD;
          -  Known history of Organic Brain Disorder.&#xD;
&#xD;
          -  Hospitalisation for an exacerbation of schizophrenia within two months prior to&#xD;
             screening and during the screening period.&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, pose an imminent risk of suicide or&#xD;
             a danger to self or others&#xD;
&#xD;
          -  Patients with the following cardiac conditions are excluded:&#xD;
&#xD;
               -  Recent myocardial infarction (&lt;I2 months)&#xD;
&#xD;
               -  QTc prolongation (screening electrocardiogram with QTc &gt; 450 msec for men, QTc &gt;&#xD;
                  470 msec for women)&#xD;
&#xD;
          -  History of QTc prolongation or using concomitant medications which prolong QTc&#xD;
             interval&#xD;
&#xD;
               -  Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia&#xD;
&#xD;
               -  Uncompensated congestive heart failure&#xD;
&#xD;
               -  Complete left bundle branch block&#xD;
&#xD;
               -  First-degree heart block with PR interval &gt; 0.22 seconds&#xD;
&#xD;
          -  Presence of cataract on Ophthalmoscopic examination (slit lamp exam).&#xD;
&#xD;
          -  History of agranulocytosis.&#xD;
&#xD;
          -  Known case of Diabetes mellitus or fasting blood glucose ≥126 mg/dl at screening&#xD;
             visit.&#xD;
&#xD;
          -  Clinically significant history or presence of any gastrointestinal pathology (e.g.&#xD;
             chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms&#xD;
             (e.g. diarrhea, vomiting), liver or kidney disease (e.g, hepatic insufficiency), or&#xD;
             other conditions known to interfere with the absorption, distribution,metabolism, or&#xD;
             excretion of the drug.&#xD;
&#xD;
          -  Concurrent Parkinson's disease&#xD;
&#xD;
          -  Clinically significant history of cataracts, tardive dyskinesia. neuroleptics&#xD;
             malignant syndrome. epilepsy or seizure.&#xD;
&#xD;
          -  Any clinically relevant neurological, endocrinal. cardiovascular. cerebrovascular,&#xD;
             pulmonary, hematological, or immunologic disease could lead to safety risk to the&#xD;
             patient upon participation in the trial or could interfere with the conduct of the&#xD;
             trial&#xD;
&#xD;
          -  Any reason that, in the opinion of the Investigator, would prevent the patient from&#xD;
             participating in the study.&#xD;
&#xD;
          -  Patients with abnormal thyroid function test at screening visit which as judged by&#xD;
             Investigator could lead to safety risk to the patient upon participation in the trial&#xD;
             or could Interfere with the conduct of the trial.&#xD;
&#xD;
          -  Patient with hyperprolactinemia at screening visit which as judged by Investigator&#xD;
             could lead to safety risk to the patient upon participation in the trial or could&#xD;
             interfere with the conduct of the trial.&#xD;
&#xD;
          -  Dementia related psychosis.&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Sachin Patkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masina hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Quetiapine fumarate</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

